$HWBK

Hawthorn Bancshares Announces Cash Dividend

Hawthorn Bancshares, Inc. (NASDAQ: HWBK) announced an increase in its quarterly cash dividend to $0.21 per common share, marking a 5% rise from the previous dividend. This dividend is payable on April 1, 2026, to shareholders of record as of March 15, 2026. Hawthorn Bancshares, headquartered in Jefferson City, Missouri, is the parent company of Hawthorn Bank, which has a 160-year history of serving families and businesses.

Original reporting
The Manila Times · GlobeNewswire
Published Jan 29, 2026, 4:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jan 29, 2026, 5:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Hawthorn Bancshares Announces Cash Dividend — source image
Decision brief

The 30-second read

$HWBKBullishMed
01

Why it matters

The dividend hike signals management's confidence and could attract income investors, potentially leading to short-term stock appreciation.

02

Market read

The news is relevant primarily to regional banking investors and income-focused traders, with limited impact on broader markets.

03

What to watch

Potential interest rate changes or economic downturns could offset positive effects of dividend hike

Relevance 6/10Timing: High, as dividend payment date is approaching

Background

Hawthorn Bancshares has a 160-year history and is a regional bank serving families and businesses in Missouri.

Company-level read

Ticker impact

$HWBKBullishHigh confidence
Context

Primary focus of the news due to dividend increase

Expected impact

Moderate upward movement expected in the short term

Evidence & confidence

Dividend hikes often signal management confidence and can attract income-focused investors, leading to short-term price appreciation.

Market effects

Positive impact on regional banking sector, potentially boosting investor confidence in regional banks

Likely limited to Missouri-based banks and regional financial institutions

Minimal, as the news pertains to a regional bank with no immediate global implications

Counterpoint

The dividend increase may be already priced in, and the stock could experience a short-term pullback after the dividend announcement

Key entities

  • Hawthorn Bancshares, Inc.

    Parent company of Hawthorn Bank, a regional bank based in Missouri.

Related articles

$HWBKMed

HAWTHORN BANCSHARES, INC. (HWBK): Completion of Acquisition or Disposition of Assets

HAWTHORN BANCSHARES, INC. (HWBK) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 PRESS RELEASE – FOR IMMEDIATE RELEASE Hawthorn Bancshares, Inc. Completes Merger with FSC Bancshares, Inc. JEFFERSON CITY, Mo., Sept. 4, 2026 /GLOBE NEWSWIRE/ -- Hawthorn Bancshares, Inc. (“Hawthorn”) (NASDAQ: HWBK), the Missouri-based holding company of Hawthorn Ban

$HWBKMed

Hawthorn Bancshares Reports Second Quarter 2026 Results

HAWTHORN BANCSHARES, INC. (HWBK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hawthorn Bancshares Reports Second Quarter 2026 Results Jefferson City, MO — July 29, 2026 — Hawthorn Bancshares, Inc. (NASDAQ: HWBK) , (the “Company”), the bank holding company for Hawthorn Bank, reported second quarter 2026 net income of $7.3 million, or earnings p

$SHOPMed

Oppenheimer sees web, commerce software Q3 backdrop improving, AI worries linger

Oppenheimer notes improved interest in web and e-commerce software ahead of Q3 results, but AI concerns remain. Shopify (SHOP) is expected to exceed revenue forecasts with strong consumer demand. Wix.com (WIX) may see slower growth due to AI shifts. GoDaddy (GDDY) is on track with forecasts, and Commerce.com (CMCM) expects revenue in line with estimates. Oppenheimer raised Shopify's price target to $205.

$RAPPMedAI 9/10

Rapport Therapeutics’ RAP-219 Hits Phase II Goals in Bipolar Mania Trial

Rapport Therapeutics (NASDAQ: RAPP) announced positive Phase II trial results for RAP-219 in bipolar mania, with plans to advance to Phase III. The drug was well-tolerated, with mild to moderate adverse events. The company aims to meet with the FDA in Q1 2027 and start Phase III trials in the second half of 2027. Rapport also expects to report long-term safety data for RAP-219 in focal onset seizures in Q4 2026.